Condition

Secondary Myelodysplastic Syndromes

ClinicalTrials.gov condition label

Clinical trials6

Recruiting0

Common interventions14

Lead sponsors shown4

Clinical trials

6 shown

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNCT01558778 · 2012-05-01

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadNCT01159067 · 2010-07-01

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantNCT00795769 · 2008-08-08

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantNCT00408681 · 2006-06-01

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantNCT00309907 · 2006-04-01

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerNCT00112593 · 1999-11-01

Common interventions

laboratory biomarker analysisOTHER2 management of therapy complicationsPROCEDURE2 cyclosporineDRUG1 deferasiroxDRUG1 etanerceptBIOLOGICAL1 fludarabine phosphateDRUG1 lithium carbonateDRUG1 methylprednisoloneDRUG1 musculoskeletal complications management/preventionPROCEDURE1 mycophenolate mofetilDRUG1 ondansetronDRUG1 peripheral blood stem cell transplantationPROCEDURE1 survey administrationOTHER1 total-body irradiationRADIATION1

Leading sponsors

Fred Hutchinson Cancer Center3 Children's Oncology Group1 City of Hope Medical Center1 Roswell Park Cancer Institute1

Trial status mix

COMPLETED4

TERMINATED1

WITHDRAWN1

Phase mix

NA3

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.